CHICAGO — Results showed a high-dose injection of allogeneic disc progenitor cells for treatment of degenerative disc disease yielded statistically significant improvements in low back pain, function, quality of life and disc volume.“Early data shows not only can we decrease patients’ back pain, improve their function as measured by the Oswestry Disability Index, [and] decrease
/PRNewswire/ DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and.
/PRNewswire/ DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and.